(3) that address prevention, including use of 
quarantine and other isolation precautions, pan-
demic influenza diagnosis, medical guidelines for use 
of anti-virals and vaccines, and professional require-
ments and responsibilities, as appropriate. 
SEC. 
113. 
RESEARCH 
AT 
NATIONAL 
INSTITUTES 
OF 
HEALTH. 
(a) IN GENERAL.—The Director of the National In-
stitutes of Health (referred to in this section as the ‘‘Di-
rector of NIH’’), in collaboration with the Director of the 
Centers for Disease Control and Prevention, and other rel-
evant agencies, shall expand and intensify human and ani-
mal research, with respect to influenza, on— 
(1) vaccine development and manufacture, in-
cluding strategies to increase immunological re-
sponse; 
(2) effectiveness of inducing heterosubtypic im-
munity; 
(3) antigen-sparing studies; 
(4) anti-virals, including minimal dose or course 
of treatment and timing to achieve prophylactic or 
therapeutic effect; 
(5) side effects and drug safety of vaccines and 
anti-virals in subpopulations;
(6) alternative routes of delivery of vaccines, 
anti-virals, and other medications as appropriate; 
(7) more efficient methods for testing and de-
termining virus subtype; 
(8) protective measures; 
(9) modes of influenza transmission; 
(10) effectiveness of masks, hand-washing, and 
other non-pharmaceutical measures in preventing 
transmission; 
(11) improved diagnostic tools for influenza; 
and 
(12) other areas determined appropriate by the 
Director of NIH. 
(b) AUTHORIZATION OF APPROPRIATIONS.—For the 
purposes of carrying out subsection (a), there are author-
ized to be appropriated such sums as may be necessary 
for each of the fiscal years 2006 through 2010. 
SEC. 114. RESEARCH AT CENTERS FOR DISEASE CONTROL 
AND PREVENTION. 
(a) IN GENERAL.—The Director of the Centers for 
Disease Control and Prevention, in collaboration with 
other relevant agencies, shall expand and intensify re-
search, with respect to influenza, on— 
(1) historical research on prior pandemics to 
better understand pandemic epidemiology, trans-
mission, protective measures, high-risk groups, and 
other lessons that may be applicable to future pan-
demic; 
(2) communication strategies for the public dur-
ing pandemic influenza, taking into consideration 
age, racial and ethnic background, health literacy, 
and risk status; 
(3) changing and influencing human behavior 
as it relates to vaccination; 
(4) development and implementation of a pub-
lic, non-commercial and non-competitive broadcast 
system and person-to-person networks; 
(5) population-based surveillance methods to es-
timate influenza infection rates and rates of out-
patient illness; 
(6) vaccine effectiveness; 
(7) systems to monitor vaccination coverage lev-
els and adverse events from vaccination; and 
(8) other areas determined appropriate by the 
Director of the Centers for Disease Control and Pre-
vention. 
(b) AUTHORIZATION OF APPROPRIATIONS.—For the 
purposes of carrying out subsection (a), there are author-
ized to be appropriated such sums as may be necessary 
for each of the fiscal years 2006 through 2010.
SEC. 115. COLLABORATION WITH NATIONAL SCIENCE 
FOUNDATION REGARDING EFFECTIVE COM-
MUNICATION STRATEGIES. 
(a) IN GENERAL.—The Secretary and the National 
Science Foundation shall collaborate to develop best prac-
tices and fund social science research toward developing 
effective communication strategies with respect to pre-
paredness for and response to pandemic influenza. 
(b) AUTHORIZATION OF APPROPRIATIONS.—For the 
purposes of carrying out subsection (a), there are author-
ized to be appropriated such sums as may be necessary 
for each of the fiscal years 2006 through 2010. 
SEC. 116. FUNDS FOR INSPECTIONS OF MANUFACTURING 
FACILITIES; POSTMARKET SAFETY. 
(a) INSPECTIONS.—With respect to facilities that 
manufacture influenza vaccine, there are authorized to be 
appropriated such sums as may be necessary for each of 
the fiscal years 2006 through 2010 for the purpose of pro-
viding additional funds to the Food and Drug Administra-
tion to conduct inspections of such facilities to determine 
whether the facilities are in compliance with regulations 
under section 501 of the Federal Food, Drug, and Cos-
metic Act (relating to adulteration). Such authorizations 
are in addition to other authorizations of appropriations 
that are available for such purpose.
(b) POSTMARKET SAFETY.—For the purpose of pro-
viding additional funds to the Food and Drug Administra-
tion to carry out postmarket safety activities with respect 
to vaccines approved under section 351 of the Public 
Health Service Act to prevent influenza, there are author-
ized to be appropriated such sums as may be necessary 
for each of the fiscal years 2006 through 2010. Such au-
thorizations are in addition to other authorizations of ap-
propriations that are available for such purpose. 
SEC. 117. COORDINATION WITH DEPARTMENT OF HOME-
LAND SECURITY. 
Consistent with section 505(a) of the Homeland Se-
curity Act of 2002, the Secretary of Health and Human 
Services shall collaborate with the Secretary of Homeland 
Security in developing and implementing a coordinated 
strategy for preparing for and responding to pandemic in-
fluenza, including carrying out such relevant activities 
under the National Response Plan (developed under 
Homeland Security Presidential Directive 5) as are con-
sistent with such section 505(a). 
SEC. 118. DEFINITION. 
For purposes of this title, the term ‘‘Secretary’’ 
means the Secretary of Health and Human Services, un-
less the context of usage indicates otherwise.